Jaguar Health Registers 40.9M Shares for C/M Capital Resale Under $40M Equity Line
JAGX sits 19% above its 52-week low of $0.725.
Summary
Jaguar Health's $40 million equity line with C/M Capital is now effective, registering 40.9 million shares for resale at a 5% discount to market. The financing provides needed capital but creates significant dilution and selling pressure.
Key Events · Financing and Capital Events · JAGX
-
Equity Line Registration Effective
Registration statement declared effective, allowing C/M Capital to resell up to 40,874,552 shares acquired under the $40 million Purchase Agreement.
-
Highly Dilutive Pricing Terms
Shares sold at 95% of the lowest of VWAP, 5-day low, or closing price, with a $1.10 floor price — a guaranteed 5% discount to market.
-
Commitment Shares Partially Issued
257,898 commitment shares already issued to C/M Capital, with 616,654 more issuable upon exercise of pre-funded warrants.
-
Going Concern Backdrop
Q2 10-Q filed August 19 disclosed $3.8M cash and a going concern warning, making this financing essential for near-term operations.
Analysis · JAGX · Life Sciences
This prospectus makes the $40 million equity line with C/M Capital fully operational, registering 40.9 million shares for resale. The pricing terms are highly dilutive: shares are sold at a 5% discount to the lowest of VWAP, 5-day low, or closing price, with a $1.10 floor price. Given the company's $3.8 million cash balance and going concern warning from the Q2 10-Q filed two days ago, this financing is critical for survival but will likely pressure the stock as C/M Capital resells shares into the market.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.73 to $85.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.